Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 575.7m

Basilea Pharmaceutica Future Growth

Future criteria checks 1/6

Basilea Pharmaceutica's earnings are forecast to decline at 25.4% per annum while its annual revenue is expected to grow at 2.8% per year. EPS is expected to decline by 26.4% per annum. Return on equity is forecast to be 44.8% in 3 years.

Key information

-25.4%

Earnings growth rate

-26.39%

EPS growth rate

Biotechs earnings growth20.5%
Revenue growth rate2.8%
Future return on equity44.79%
Analyst coverage

Good

Last updated04 Nov 2025

Recent future growth updates

Recent updates

Basilea Pharmaceutica (VTX:BSLN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Aug 29
Basilea Pharmaceutica (VTX:BSLN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Emerging Markets And Drug Resistance Will Drive Global Expansion

Key Takeaways Expanding global sales of key anti-infective drugs and successful commercialization partnerships are driving top-line growth and increased royalty income. Strategic pipeline development, acquisitions, and a partnership-driven model support profit growth, regulatory momentum, and future market expansion.

Benign Growth For Basilea Pharmaceutica AG (VTX:BSLN) Underpins Its Share Price

Jul 29
Benign Growth For Basilea Pharmaceutica AG (VTX:BSLN) Underpins Its Share Price

Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

Apr 10
Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

Estimating The Intrinsic Value Of Basilea Pharmaceutica AG (VTX:BSLN)

Apr 04
Estimating The Intrinsic Value Of Basilea Pharmaceutica AG (VTX:BSLN)

There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings

Feb 26
There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings

Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt

Feb 20
Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01
Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24
Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18
If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Earnings and Revenue Growth Forecasts

SWX:BSLN - Analysts future estimates and past financials data (CHF Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272946348504
12/31/20262545542416
12/31/20252213834406
6/30/2025236737879N/A
3/31/2025222757577N/A
12/31/2024209787374N/A
9/30/2024179384142N/A
6/30/2024149-1910N/A
3/31/202415351112N/A
12/31/2023158101314N/A
9/30/2023166332022N/A
6/30/2023175562729N/A
3/31/2023161341618N/A
12/31/20221481247N/A
9/30/20221506-21N/A
6/30/20221521-8-5N/A
3/31/2022150-3-20-18N/A
12/31/2021148-7-33-32N/A
9/30/2021130-26-41-40N/A
6/30/2021112-45-50-48N/A
3/31/2021120-30-53-51N/A
12/31/2020128-15-56-54N/A
9/30/2020134-6-55-53N/A
6/30/20201413-53-52N/A
3/31/2020137-10-58-58N/A
12/31/2019134-22-64-64N/A
9/30/2019135-23-64-64N/A
6/30/2019136-24-65-64N/A
3/31/2019134-28N/A-72N/A
12/31/2018133-31N/A-79N/A
9/30/2018124-26N/A-42N/A
6/30/2018115-21N/A-5N/A
3/31/2018108-20N/A7N/A
12/31/2017102-19N/A19N/A
9/30/201792-32N/A-19N/A
6/30/201782-44N/A-58N/A
3/31/201774-48N/A-66N/A
12/31/201666-51N/A-75N/A
9/30/201662-55N/A-89N/A
6/30/201658-59N/A-102N/A
3/31/201655-61N/A-85N/A
12/31/201553-62N/A-68N/A
9/30/201550-57N/A-57N/A
6/30/201547-52N/A-46N/A
3/31/201545-47N/A-59N/A
12/31/201442-42N/A-71N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BSLN's earnings are forecast to decline over the next 3 years (-25.4% per year).

Earnings vs Market: BSLN's earnings are forecast to decline over the next 3 years (-25.4% per year).

High Growth Earnings: BSLN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BSLN's revenue (2.8% per year) is forecast to grow slower than the Swiss market (3.9% per year).

High Growth Revenue: BSLN's revenue (2.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BSLN's Return on Equity is forecast to be very high in 3 years time (44.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/15 08:59
End of Day Share Price 2025/11/14 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Basilea Pharmaceutica AG is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research